Fresenius Kabi USA, LLC has recalled 16,986 vials of DOXOrubicin Hydrochloride Injection, USP (10 mg / 5 mL). This recall was initiated after testing discovered trace amounts of another drug, octreotide, within the product. This cross-contamination can lead to patients receiving unintended medication during their treatment. Consumers should contact their healthcare provider or pharmacist regarding any use of the affected medication.
The presence of trace amounts of octreotide in a doxorubicin injection means patients are being exposed to an unintended pharmacological agent. This cross-contamination can cause unexpected side effects or interfere with the primary cancer treatment being administered.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.